Tanner Industries is a family owned and operated distributor of anhydrous and aqua ammonia.

Gelest, Inc., headquartered in Morrisville, PA, USA, was founded in 1991 to serve the advanced technology applications markets and is recognized worldwide as an innovator, manufacturer and supplier of Organo-Silicon and Metal-Organic materials for commercial production and R&D support. Since its inception, Gelest, Inc. has continuously added experts in the fields of silanes, silicones, and metal-organics. The technical staff includes individuals with extensive hands-on experience and academic credentials (see Management Team). Joint developments between customers and staff have led to an increased product offering from several hundred materials to the current listing of several thousand materials. The company has focused its research and development efforts toward expanding the offering of Group 4A and 4B analogs. Gelest, Inc. offers the most comprehensive selection of silane, silicone, and metal-organic materials in the world

Polysciences, Inc. is a manufacturer of fine and specialty chemical materials for industrial, consumer, academic research and biotechnology applications. For six decades Polysciences, Inc. has developed and manufactured a wide range of products for customers working within the life sciences, histology, microsopy, immunology, monomer and polymer, microparticles, electronic chemicals and personal care markets.

Veltek Associates, Inc. designs innovative solutions to address the control of particulate and microbial contamination in pharmaceutical and biotechnology operations worldwide. VAI strives to develop meaningful technical relationships with our clients to ensure that VAI products meet, if not exceed, their unique requirements. The products from VAI’s four divisions build upon each other, making the company a full-circle, single-source supplier able to address any pharmaceutical or biotechnology contamination control requirement. VAI has been an industry leader since 1981 and has over 135 US and International Patents. We are committed to continual innovation and improvement in our products to satisfy current and future regulatory requirements. Our corporate capabilities and pharmaceutical experience provide the framework for continuing VAI’s leadership in contamination control.

Resin Solutions is a global manufacturer of specialty low molecular weight functional additives based on a variety of unique chemistries. Included are functional diene-based polymers, (meth)acrylate functional metallic monomers, and aromatic and aliphatic hydrocarbon resins based on C5 and C9 feed streams that can serve a wide variety of applications in the adhesives, rubber and thermoplastics industries.

Zydus Pharmaceuticals (USA) Inc. has been providing quality, affordable generic drugs to the US market for over 15 years. Zydus USA is the US generics division of Zydus Lifesciences Limited and has grown to become one of the top 10 pharmaceutical companies in the US by unbranded dispensed prescriptions. Exceptional service to both customers and patients who rely on our products has been a key driver for the company’s success. With a mission of growth, Zydus USA is focused on expanding its portfolio of complex generics, including modified release oral solids, transdermals, injectables, and oral suspensions. Product-specific questions should be directed to Zydus USA’s Medical Affairs team. To report a product complaint or adverse event related to a Zydus USA product, please contact us at 877-993-8779 Prompt 2 or [email protected]. You are also encouraged to report negative side effects of prescription drugs to the FDA (www.fda.gov/medwatch or call 1-800-FDA-1088).

We are a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists. Our first commercial product, XHANCE® (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing our proprietary Exhalation Delivery System™ (EDS®) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and, if approved, chronic rhinosinusitis without nasal polyps (also known as chronic sinusitis). In September 2017, the U.S. Food and Drug Administration (FDA) approved XHANCE for the treatment of nasal polyps in patients 18 years of age or older. XHANCE was made widely available through commercial channels in April 2018. In March and June 2022, we announced positive top line results from our two Phase 3b clinical trials (ReOpen1 and ReOpen2) of XHANCE for a follow-on indication for the treatment of chronic sinusitis. In February 2023, we submitted a prior approval efficacy supplement (sNDA) to support the approval of a new indication for XHANCE for the treatment of chronic rhinosinusitis. If the sNDA is approved, XHANCE has the potential to be the first drug therapy approved by the FDA for the treatment of chronic sinusitis. As of February 20, 2023, we had a total of 141 full-time employees all of whom are in the United States, and no part-time employees. Culture is a critical element in the management of our organization. Our colleagues are focused on driving our business with the Optinose values as the foundation for all our efforts. Our goal is that each colleague feels a deep connection to what they do, loves coming to work and is aligned to our One Mission – to improve lives. Our values of Authenticity, Fearless Conversations, Friendship, Openness, Perseverance and Possibility Thinking guide our actions and decisions.

ResinTech Inc., an acknowledged leader in ion exchange, manufactures a broad range of ion exchange resins for water and waste water treatment, including deionization,softening, metals removal, product purification, resource recovery, and pollution control. In addition to its ion exchange resins, ResinTech supplies activated carbon and inorganic selective exchangers. ResinTech has developed an application technology resource group that includes state-of-the-art laboratories and a group of scientists dedicated to expanding the frontiers of application technology. This group is put to use whenever product or process recommendations are requested, assuring customers get the most cost-effective approach to achieving their process goals.

Jackson ImmunoResearch Laboratories, Inc. specializes in the manufacture of secondary antibodies and complementary products for life science applications. Maintaining the highest standards in our research, manufacturing and operations contributes to product quality, long term product consistency and reliable performance.

Founded in 1984, Polytek® Development Corp. is a leading manufacturer of specialty polymers for mold making and casting applications across industrial and consumer sectors. We are here to support the engineers, DIYers, manufacturers, craftsmen, designers, makers, artists, and fabricators that create products that restore and improve physical infrastructure, support exciting hobbies, transform manufacturing processes, entertain on the big screen, inspire others, and improve our lives. Polytek’s collective mission is to design and manufacture the highest-performance line of mold making and casting products and to provide our customers with unmatched, industry-setting technical support and customer service. In doing so, we are committed to helping our customers realize the greatest value from the use of our products and resources. In the end, our success is defined by yours.

Inolex is a fiercely independent company that designs sustainable ingredients for health, beauty, and wellness. We don’t swim with the current; we create it. We envision and realize solutions to advance the needs of our customers. We challenge ourselves and the industry to think differently. Honoring nature, we design emerging technologies that ensure the safe and optimum performance of leading brands in more than 85 countries. Our designers are guided by the Principles of Green Chemistry, to invent the future of sustainable ingredient platforms. By balancing conscious science with nature and artistry, our imaginative approaches become the building blocks for exceptional products that care for people and our planet. We are Inolex. Thinkers, Designers, Creators, and Rebels.

Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). We believe the key to success in developing a functional cure involves suppressing HBV DNA, reducing surface antigen, and boosting HBV-specific immune responses. Our pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. Imdusiran is the only RNAi that has generated meaningful clinical data demonstrating an impact on both surface antigen reduction and reawakening of the HBV-specific immune response. Imdusiran is currently in two Phase 2a combination clinical trials. AB-101 is currently being evaluated in a Phase 1a/1b clinical trial. We are also exploring oncology applications for our internal PD-L1 portfolio.